An Open-Label, Neoadjuvant Phase 2 Clinical Trial Comparing the Effects of AR Inhibition with and without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer: An outcome report

Mix methods approach to explore patients’ perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance

Testing the external validity of CARMENA trial comparing Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction: An Open-Label Phase 1 Clinical Trial

An Anatomic Classification System for Local Recurrence Following Resection of Intermediate and High Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Trial

Response to Apalutamide (APA) Among Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier (GC) Score

RATES AND PATTERNS OF METASTASES IN PATIENTS WITH NODE-NEGATIVE PROSTATE CANCER AT RADICAL PROSTATECTOMY THAT EXPERIENCE PSA FAILURE: POST-HOC ANALYSIS OF RTOG 9601 TRIAL DATA

Impact of bone-targeted therapies in patients with chemotherapy-naive metastatic castration-resistant prostate cancer on enzalutamide: a post hoc analysis of PREVAIL

Improving the safety and efficacy of Photodynamic therapy for NMIBC– Intravesical Ruthenium (II)-photosensitizer and light dosimetry in a phase 1B clinical trail

A Urinary Proteomics Analysis of Patients Treated with Neoadjuvant Axitinib for Non-metastatic Clear-Cell Renal-Cell Carcinoma: Analysis From a Phase II Trial

Comparison of surveillance regimens for low risk non-muscle invasive bladder cancer: A Pilot Study

A Phase 1 safety study of Oncofid-P-B administered for 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS): Preliminary results

Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: final analysis of the EQUINOXE study

Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR)–initial results of a phase II trial

Patients perspective on cytoreductive nephrectomy after CARMENA